SCOPUS 정보 검색 플랫폼

Clinical Neurology and Neurosurgery

Volumn 115, Issue 9, 2013, Pages 1851-1852

Severe acute motor neuropathy after treatment with triple tyrosine kinase inhibitor BIBF 1120 (Nintedanib)

(4) Patejdl, R a Markmann, S a Benecke, R a Wittstock, M a

a UNIVERSITY OF ROSTOCK (Germany)

Author keywords

Angiogenic agents; BIBF 1120; Chemotherapy induced peripheral neuropathy; Ovarian cancer; Tyrosine kinase inhibitors

Indexed keywords

CARBOPLATIN; IMMUNOGLOBULIN; NINTEDANIB; PACLITAXEL;

ACUTE MOTOR NEUROPATHY; ADD ON THERAPY; ADULT; ARTICLE; BILATERAL OVARIAN SEROUS CYSTADENOCARCINOMA; CANCER STAGING; CASE REPORT; CYSTADENOCARCINOMA; DENERVATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; FEMALE; HUMAN; MOTOR NEUROPATHY; MOTOR UNIT POTENTIAL; MUSCLE ACTION POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PARESTHESIA; PLASMAPHERESIS; PROTEIN CEREBROSPINAL FLUID LEVEL; QUADRIPLEGIA; REINNERVATION; TENDON REFLEX; TREATMENT DURATION;

ANGIOGENIC AGENTS; BIBF 1120; CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY; OVARIAN CANCER; TYROSINE KINASE INHIBITORS;

ANTINEOPLASTIC AGENTS; AXONS; CYSTADENOCARCINOMA; ELECTRODIAGNOSIS; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; MOTOR NEURON DISEASE; NEURAL CONDUCTION; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 84887626852 PISSN: 03038467 EISSN: 18726968 Source Type: Journal
DOI: 10.1016/j.clineuro.2013.01.011 Document Type: Article

Times cited : (5)

References (5)

1
- 77953709859
- Treatment of ovarian cancer by monoclonal antibodies
- S. Mabuchi, and T. Kimura Treatment of ovarian cancer by monoclonal antibodies Discovery Medicine 9 2010 197 203
- (2010) Discovery Medicine , vol.9 , pp. 197-203
- Mabuchi, S.¹ Kimura, T.²

2
- 77951895481
- A phase i open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
- A. Du Bois, J. Huober, P. Stopfer, J. Pfisterer, P. Wimberger, and S. Loibl A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies Annals of Oncology 21 2010 370 375
- (2010) Annals of Oncology , vol.21 , pp. 370-375
- Du Bois, A.¹ Huober, J.² Stopfer, P.³ Pfisterer, J.⁴ Wimberger, P.⁵ Loibl, S.⁶

3
- 79955120762
- Peripheral neuropathy as an adverse effect of imatinib therapy
- G. Chakupurakal, R.J. Etti, and J.A. Murray Peripheral neuropathy as an adverse effect of imatinib therapy Journal of Clinical Pathology 64 2011 456
- (2011) Journal of Clinical Pathology , vol.64 , pp. 456
- Chakupurakal, G.¹ Etti, R.J.² Murray, J.A.³

4
- 58149267547
- High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers
- H. Sharp, J.C. Morris, C. van Waes, D. Gius, T. Cooley-Zgela, and A.K. Singh High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers American Journal of Clinical Oncology 31 2008 557 560
- (2008) American Journal of Clinical Oncology , vol.31 , pp. 557-560
- Sharp, H.¹ Morris, J.C.² Van Waes, C.³ Gius, D.⁴ Cooley-Zgela, T.⁵ Singh, A.K.⁶

5
- 1642263338
- Targeted disruption of the FGF-2 gene affects the response to peripheral nerve injury
- J. Jungnickel, P. Claus, K. Gransalke, M. Timmer, and C. Grothe Targeted disruption of the FGF-2 gene affects the response to peripheral nerve injury Molecular and Cellular Neurosciences 25 2004 444 452
- (2004) Molecular and Cellular Neurosciences , vol.25 , pp. 444-452
- Jungnickel, J.¹ Claus, P.² Gransalke, K.³ Timmer, M.⁴ Grothe, C.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.